Pycnogenol® intake for 6 months in patients with persistent symptoms of Lyme disease can help relieve the main symptoms by reducing inflammation and oxidative stress.
Supplementary management of chronic Lyme disease with Pycnogenol®.
AI Summary
Key Findings
Abstract
BACKGROUND: The aim of this pilot supplement registry study was to investigate the efficacy of the anti-inflammatory supplement Pycnogenolin subjects with history of Lyme disease and persistent symptoms with no active bacteria present (Stage 2 and 3 of Lyme disease), on the reduction of inflammation and the relieve of the main symptoms. There is currently no specific treatment for this condition. METHODS: The subjects were divided into two groups: one group received 150 mg/day of Pycnogenolalongside standard management, while the control group received only standard management. The observation period lasted for six months. RESULTS: Forty subjects with history of Lyme Disease and persistent symptoms completed the study: 20 in the Pycnogenolgroup, 20 in the control group. No side effects from the supplementation were observed. The tolerability was optimal as no supplemented subject had to stop management and compliance was optimal with 97% of the Pycnogenolcapsules correctly used. The two groups were comparable for sex, age distribution and for their main clinical findings and signs/symptoms at inclusion. During the study, corticosteroids at low dose were used on demand in 10% of subjects using Pycnogenoland significantly more, in 45% of the control patients (P
Affiliation
Maria R Cesarone
External References
- PubMed ID:
- 40371616
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.